SYNCOM/SE/2025-26 19th May, 2025

Online filing at: www.listing.bseindia.com and https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp

To, BSE Limited Phiroze Jeejeebhoy Tower,

Dalal Street, Mumbai (M.H.) 400 001 BSE CODE:524470

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai- 400051 NSE SYMBOL: SYNCOMF

Subject: Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015-Submission of Standalone & Consolidated Audited Financial Results along with Audit Report, Statement of Assets and Liabilities and Cash Flow for the year ended on 31st March, 2025.

Dear Sir/Ma'am,

Pursuant to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Standalone & Consolidated Audited Financial Results along with Auditors' Report thereon by Statutory Auditors, Statement of Assets and Liabilities and Cash Flow for the quarter/year ended on 31st March, 2025, in PDF Format, which were approved by the Audit Committee and Board of Directors at their meeting held on Monday, 19th May, 2025.

Since, the Auditor's Report is self-explanatory and has no modification/qualification; it needs no further comments from the Company.

We are also in process of filing the aforesaid financial results in Integrated XBRL format within the stipulated time and the same shall also be hosted on the website of the company.

The Financial Results will also be published in widely circulated English and Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period.

The Board Meeting commenced at 4:00 P.M. and concluded at 5:45. P.M.

You are requested to take on record the Audited Financial Results, Statement of Assets and Liabilities and Cash Flow along with Auditor's Report for your reference and record.

Thanking You, Yours Faithfully, For, SYNCOM FORMULATIONS (INDIA) LIMITED CS VAISHALI AGRAWAL COMPANY SECRETARY & COMPLIANCE OFFICER Encl: a/a Vaishali Agrawal Digitally signed by Vaishali Agrawal Date: 2025.05.19 17:46:24 +05'30'

	SYNCOM FORMULATIONS (INDIA) LIMITED
	Regd. Off :- 7,Niraj Industrial Estate, Off Mahakali Caves Road,Andheri (E) Mumbai-400093
	Works:- 256-257, Sector - 4, Pithampur, Dist: Dhar-454775
	E Mail:- [email protected], Website:- www.sfil.in, CIN :- L24239MH1988PLC047759
	STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2025
						Rs. In Lacs except EPS
s.	Particulars		Quarter Ended
N oO.						Year Ended
		31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024
1		Audited	Unaudited	Audited	Audited	Audited
	Revenue from Operations	14846.33	12702.92	7326.63	46284,93	25835,96
2 3	Other Income	690,34	382.49	287,08	1719.12	1310.06
4	Total Income (1 +2) JEXPENSES	15536.64	13085,44	7613.71	48004,05	27146,02
	(a) Cost of materials consumed
	(b ) Purchases of Stock-in-Trade	8016.05 1568.48	7626.18 712,91	3787.87	27802.93	13152.91
	(¢ ) Changes in inventories of finished goods, Stock-in- Trade			488.61	3947.71	2620.83
	and work-in-progress (d) Employee benefits expense	438.80	323.08	(20.04)	(1062.24)	(218.10)
	(e ) Finance costs	1497.47	1394.75	869,23	\$217.37	3505.77
	(1) Depreciation and amortization expense	8.92	21.23	116.97	85.02	444.87
	(9) Other expenses	128,64	130.75	129.77	519,39	472.23
	Total expenses ( 4)	1878.33	1186.03	1320.45	5028.63	3989.12
5	Profit/(loss) before exceptional items and tax (3- 4)	13236,69	11394.93	6692.86	41638,84	23967,63
6	Exceptional Items	2299.95	1690.48	920.85	6465.24	3178.39
7	Profit/(loss) before tax (5 - 6)	0.82	0.00	0.00	0.58	(2.39)
8	Tax expense:	2300.77	1690.48	920.85	6465.82	3176.00
	(1) Current tax	450.12	402.82	241,73	1445.26	758.25
g	(2) Deferred tax	100,45	8.54	4.27	133,38	55.43
	Profit (Loss) for the period from continuing operations (7-8)	1750.20	1279.12
10	Profit/(loss) from discontinued operations	0.00	0.00	674,85 0.00	4887.18 0.00	2362.32 0.00
4 12	Tax expense of discontinued operations Profit/(loss) from Discontinued operations (after tax) (10-11)	0,00	0.00	0.00	0.00	0.00
		0.00	0.00	0.60	0.00	0.00
13	Profiti(loss) for the period (9 +12)	1750.20	1279.12	674.85	4887.18	2362.32
14	Other Comprehensive Income
	A(/)Items that will not be reclassified to profit or loss	0.00	0.00	0,00	0.00	0.00
	(7) Income tax relating to items that will not be reclassified to profit or loss	0,00	0.00	0.00
	B (/) Items that will be reclassified to profit or loss	(228.19)	18.40	164,57	0.00 458.02	0.00 681.39
	(ii) Income tax relating to items that will be reclassified to profit or loss
15	Total Comprehensive Income for the period (XIIl+XIV)	0.00	0.00	0.00	0.00	0.00
	(Comprising Profit (Loss) and Other Comprehensive Income
	for the period)	1622.01	1297.52	839.42	5345.20	3043.71
16 17	Paid up Share Capital of the Company (Face Value 1/-) Reserves excluding revaluation reserves	9400.00	9400.00	9400.00	9400.00	9400.00
18		0,00	0.00	0,00	24590,38	19245.18
	Earnings per equity share (for continuing operation): (1) Basic
	(2) Diluted	0.16 0.16	0.14	0.09	0.57	0.32
19	Earnings per equity share (for discontinued operation):		0.14	0.09	0.57	0.32
	(1) Basic	0.00	0,00	0.00	0,00
	(2) Diluted	0.00	0.00	0.00	0.00	0,00 0.00
20	Eamings per equity share (for discontinued & continuing operations)
	(1) Basic	0.16	0.14	0.09
	(2) Diluted	0.16	0.14	0.09	0.57 0.57	0.32 0.32

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

^EMail:- [email protected], Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY AND YEARLY AUDITED RESULTS

			Quarter Ended			Year to date Ended
S.No.	Particulars	31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024
		Audited	Unaudited	Audited	Audited	Audited
4	[Segment Revenue
	a) Pharmaceuticals Drugs & Formulations	15,214.89	12,766.27]	7,302.70)	46, 784,92	25,672.79)
	b) Trading of Commodities Ic) Renting of Property	213.45	228,88]	213,93)	825.84	1,071.34
		108.30	90,26	97.08)	393.29	401,89)
	Total Segment Revenue	15,536.64)	13,085.41	7,613.71	48,004.05)	27,146.02)
	Less: Inter Segment Revenue	+	+	+	+
	Total Income	15,536.64)	13,085.41	7,613.71	48,004.05]	27,146.02]
2	Segment Results Profit(+)/Loss(-) before tax
	and interest from each segment
	a) Pharmaceuticals Drugs & Formulations	2,205.69]	1,626.16]	939.46	6,169.90]	3,232.76)
	b) Trading of Commodities	4.19	3.37]	19.92)	20.35	18.49}
	c) Renting of Property	99.81	82.18}	78.44	360.59}	369,62}
	Total Profit before tax and Interest	2,309.69	1,711.74	1,037.82]	6,550.84	3,620.87
	Less: i) Interest	8.92	21.23)	116.97]	85,02)	444,87
	ii) Other Un-allocable Expenditure	+	-	+	4	4
	Profit before tax	2,300.77	1,690.48	920.85)	6,465.82)	3,176.00}
3	}(Segment Asset-Segment Liabilities)
	Segment Asset
	a) Pharmaceuticals Drugs & Formulations	35,752.04	32,536.81	33,390.18)	35,752.01	33,390.18}
	b) Trading of Commodities	448,67)	890.60)	1,026.45)	448.67	1,026.45}
	c) Renting of Property	4,767.98	4,733.45)	4,733.45)	4,767.98
	Total Segment Asset	40,968.66)	38,160.86)	39,160,08	40,968.66)	4,733.45)
	Un-allocable Assets	c		7		39,150.08 +
	Net Segment Asset	40,968.66	38,160.86	39,150.08	40,968.66)	39,150.08}
	'Segment Liabilities
	la) Pharmaceuticals Drugs & Formulations	6,754.47,	5,460.01	10,181.37]	6,754.47	10,181.37,
	b) Trading of Commodities	82.76]	155,00	151.93	82.76	151,93)
	c) Renting of Property	141.04)	77.48)	171.60)	141.04	171.60)
	Total Segment Liabilities	6,978.27	5,692.49)	10,504.90)	6,978.27]	10,504.90]
	Un-allocable Liabilities	a		+	+	-
	Net Segment Liabilities	6,978.27]	5,692.49}	10,504,90)	6,978.27	10,504.90

¹The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 19/05/2025

²These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.

³The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required,

⁴The Standalone Statement of Assets and Liabilities as at 31st March, 2025 and the Standalone Statement of Cash Flow is provided as an annexure to this statement.

⁵As required under Regulation 33 of SEB! (LODR) Regulations, 2015 the Auditor's report provided by the Statutory Auditors have carried out Audit books of Accounts for the company Financial year 2024-2025 and issued us an Audit Report with an unmodified opinion on Audited financial Results for the Quarter / Year ended 31st March, 2025 Therefor the Is not required to give statement of Impact of Audit Qualification for Audit report with modified opinion

⁶Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.

⁷The figures of the Last Quarter are the balancing figures between the audited figures in respect of full financial year & the published year to date figures upto 3rd quarter of that financial year

Vijay Shankarlal Bankda i Managing Director : DIN: 00023027

Regd. Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road, Andheri (E) Mumbai-400093 Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

^EMail: [email protected], Website:- www. sfil,in, CIN :- L24239MH1988PLC047759

Standalone Statement of Assets & Liabilities as at 31/03/2025
Particulars		31-03-2025	34-03-2024
ASSETS	Rs. In Lacs	Audited	Audited

Non-current assets
(a) Property, Plant and Equipment
(b) Capital Work in Progress		7,752.61	7,230.60
(c) Intangible assets		-	-
(d) Investment Property		4.72 4,733.44	11.05
(e) Financial Assets		-	4,733.44
(i) Investments		364,82	251.92
(ii) Fixed Deposits & Accrued Interest		1,218.67	586.64
(iii) Deposits		66.62
(f) Other Non Current Assets		81.58	51,90 20.56
Current assets		-
(a) Inventories		4,129.29	2,108.15
(6) Financial Assets		-
(i) Investments		8,921.64	6,369.94
(ii) Trade Receivables		10,694.43	9,321.46
(iii) Cash And Cash Equivalents		69.23	6,335.05
(iv) Bank Balances other than (iii) above		-	448,21
(v) Deposits		353.22	412.00
(vi) Loans & Advances		539.29	429.33
(d) Other Current Assets		2,039.10	839.83
Total		40,968.66	39,150.08

EQUITY AND LIABILITIES
Equity
(a) Equity Share Capital (b) Other Equity		9,400.00	9,400.00
Liabilities		24,590.38	19,245.18
Non Current Liabilities
(a) Financial Liabilities
(i) Trade and other Deposits
(b) Provisions		133.35	171.60
(c) Deferred Tax Liabilities (Net)		416.84	330.38
Current liabilities		631.05	497.67
(a) Financial liabilities		-
(i) Borrowings		~
(ii) Trade Payables		404.32 -	7,165.03
Total Outstanding Dues of Micro Enterprises and Small Enterprises		2,278.89	586.77
inn Dues of Creditors other than Micro Enterprises and Small		4 993.30	836,33
(iii) Other Financial Liabilities
(b) Other Current Liabilities		213,00	213.62
(c) Provisions		495.68	358.04
Total		411.85	345.46
		40,968.66	39,150.08

ncom Formulations (India) Limited a 1 yp Vijay Shankarlal Bankda ' Managing Director] DIN: 00023027

Place: Indore Date: 19/05/2025

		SYNCOM FORMULATIONS (INDIA) LIMITED
--	--	-------------------------------------	--	--

Regd.Off ;- 7,Niraj Industrial Estate,Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pilhampur, Dist: Dhar-454775

E Mail:- [email protected], Website: www.sfil.in, CIN : L24239MH1988PLC047759 Standalone Cash Flow Statement for the year ended 31/03/2025
Particulars	31-03-2025	31-03-2024

Rs. In Lacs	Audited	Audited
Cash Flow from Operating Activities
Profit before extraordinary item and tax	6,465.24	3,178.39
Adjustments for:	-	-
Gain on Sale of Machinery / (Loss on Sale of Vehicle)	0.58	(2.39)
Gain/(Loss) on Actuarial valuation of employee benefits	(28.91)	(18,50)
Depreciation	519.39	472,23
Depreciation Written Back	(39.14)	(1.74)
Finance Costs	85.02	444,87
Other Income	(1,633.53)	(1,221,35)
Operating Profit before working capital changes	5,368.65	2,851.51
Changes in Working Capital
Inventory	(2,021.14)	(30,76)
Trade Receivables	(1,372.97)	(1,807.63)
Loans & Advances	(109.96)	(151.33),
Other Current Assets	(1,140.49)	(128.37)
Trade Payables	2,849.09	(617.75)
Other Financial Liabilities	(0.62)	11.44
Other Current Liabilities	137,64	(47.21)
Short Term Provisions	66.39	84.59
Changes in Working Capital	(1,592.06)	(2,687.02)
Cash Generated from Operations before Tax	3,776.59	164.49
Less: Income Tax Paid	1,445.26	758.25
Net Cash From Operating Activities	2,331.33	(593.76)
Cash Flow from Investing Activities
Change in Property Plant and Equipment, Intangible Assets and
Capital Work in Progress as	(895.83)	(813.64)
Change in Investment Property	-	-
Change in Fixed Deposit & Accrued Interest	(183,82)	7,313.19
Change in Deposits	(14.72)	(2,15)
Change in Other Non Current Assets	(61,02)	185.58
Change in Trade & Other Deposits	(38.25)	17.46
Other Income	1,633.53	1,221.35
Change in Investment	(2,177.67)	491.17
Net Cash from Investing Activities	(1,837.88)	8,382.96
Cash Flow from Financing Activities
Finance Costs	(85.02)	(444,87)
Change in Long Term Liabilities	86.46	61.14
Issue of Warrants & Share capital	-	-
Dividend Paid	-	-
Borrowings	(6,760.71)	(1,153.12)
Net Cash from Financing Activities	(6,759.27)	(1,536.85)
Net Decrease in Cash & Cash Equivalents
Cash & Cash Equivalents at the beginning of the Period	(6,265.82) 6,335.05	6,252.35
Cash & Cash Equivalents at the End of Period	69.23	82.70
		6,335.05

Place: Indore	For, Syncom Formulations (India) Limited aa
Date: 19/05/2025	OLA Py, Vijay Shankarlal Bankda
	Managing Director, DIN: 00023027

SANJAY MEHTA & ASSOGIATES

338, Saket Nagar, lndore - 452 018 (M.P,)

Results ended on 3 lndependent Auditor's Report on Audited Standalone Quarterly Financial Results and year to Date ObliFations and Disclosure Requirements) ReRuiations, 2015, as amended

To,

The Board of Directors Syncom Formulations (tndia) Limited

Opinion

We have audited the accompanying Statement of quarterly and year to date standalone Financial Statements of Syncom Formulations (lndia) Limited ('the Company') for the quarter and year ended 31't March, 2025 ('the Statements), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"),

ln our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

i. presents financial results in accordance with the requirements of regulation 33 of the listing regulations read with SEBI Circular ClFlCFDlFACl62l2076 dated 5 July 2016 (hereinafter referred to as SEBI Circular); and
ii, give a true and fair view in conformity with the applicable lndian Accounting Standards (lND AS) prescribed under section 133 of the Companies Act, 2013 (The Act), read with relevant rules issued thereunder and other accounting principles generally accepted in lndia, of the standalone net profit after tax and other comprehensive income and other financial information of the company for the quarter ended March 3t,2025 as well as the year to date results for the period from April 1,2024 to March 3!,2025.

Basis for Opinion

We conducted our audit of the statement in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Rct). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Stondolone Finonciol Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the lnstitute of Chartered Accountants of lndia together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 201,3 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

This Statement has been prepared on the basis of the standalone annual audited financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the statement that gives a true and fair view of the

net profit and .other comprehensive income and other financial information of the Company in accordance with the accounting principles generally accepted in lndia, including IND AS prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in lndia, and in compliance with Regulation 33 of the Listing Regulations including SEBl circular. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and pruclent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

ln preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as ^a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not ^a guarantee that an audit conducted in accordance with Standard on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professionaljudgment and maintain professional skepticism throughout the audit. We also:

ldentify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls.
Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors/management.

o Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. lf we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
o Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
o Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the Financial Results.

Materiality is the magnitude of misstatements in the Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the result of our work; and (ii) to evaluate the effect of any identified misstatements in the Financial Results.

We communicate with those charged with governance regardlng, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the financial results for the quarter ended 31 March 2025,being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.

Place: lndore Date:19-05-2025

FOR, SANJAY MEHTA & ASSOCIATES CHARTERED NTANTS F.R. NO.01

MANISH MITTAL PARTNER M. NO. 079452 UDIN : 25079452BM1GUC2989 4x\$ !(ruoone),e qv7

	Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093
		Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
	E Mail:- [email protected], Website:- www.sfil.in, CIN :- L24239MH1988PLC047759
	CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARGH 2025
s. i					Rs. In Lacs except EPS
o.	Particulars		Quarter Ended
					Year Ended
		31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024
1	JRevenue from Operations	Audited	Unaudited	Audited	Audited	Audited
2	Other Income	14,887.64	12,753.32	7,457.29	46,501.26	26,338.71
3	Total Income (1 +2)	694.28	403,70	309.84	1,743.40	1,352.59
4	EXPENSES	15,581.92	13,157.02	7,767.13	48,244.66	27,691.30
	(a) Cost of materials consumed	8,016.05	7,626.18	a
	(b ) Purchases of Stock-in-Trade	1,579.28	722.62	3,787.87 501.95	27,802.93 3,996.75	13,152.91
	( c ) Changes in inventories of finished goods, Stock-in- Trade land work-in-progress					2,710.59
	(d) Employee benefits expense	441,21	316.76	(20.04)	(1,066.15)	(175,46)
	(@) Finance costs	1,497.47	1,394.75	869.23	5,217.37	3,605.77
	(f) Depreciation and amortization expense	11.68 428.64	19.82 430.75	119.51	86.49	447.44
	(9) Other expenses	1,578.40		129,77	519.39	472.23
	Total expenses (4)		1,219.92	1,375.84	5,137.19	4,180.16
5	Profiti(loss) before exceptional items and tax (3- 4)	13,252.73 2,329.19	11,430.80	6,764.13	41,693.97	24,293.64
6	JExceptional Items	0.82	1,726.22 5	1,003.00	6,550.69	3,397.69
i	[Profiti(toss) before tax (5-6)	2,330.04	1,726.22	-	0.58	(2.38)}
8	Tax expense:			1,003.00 -	6,551.27	3,395.30
	(1) Current tax (2) Deferred tax	460.00	417.61	258,28	1,474.43	808.45
9	Profit (Loss) for the period from continuing operations (7-8)	100.58	8.41	4.27	133.38	55.43
		1,769.43	1,300.20	740.45
10 14	Profit(loss) from discontinued operations	=	z	ws	4,943.46	2,531,42 -
12	Tax expense of discontinued operations Profit/(loss) from Discontinued operations (after tax) (10-11)	-	-	-	:	-

13	Profit/(loss) for the period (9 + 12 )	1,769.43	41,300.20	740,45	4,943.46
14	Other Comprehensive Income					2,531.42
	A(i)ltems that will not be reclassified to profit or loss	6s	=		#
	(i) Income tax relating to items that will not be reclassified to profit or loss
	° (i) Items that will be reclassified to profit or loss	= (228.19)	18.40	: 164,57	2	:
	(i) Income tax relating to items that will be reclassified to profit				458,02	681.39
	or loss	x	i	7	-	e
15	Total Comprehensive Income for the period (XIll+XIV) (Comprising Profit (Loss) and Other Comprehensive Income
	for the period)	1,541.24	1,318.60	905.02
16	Paid up Share Capital of the Company (Face Value 1/-)	9,400.00	9,400.00	9,400.00	5,401.48 9,400.00	3,212.81
17	Reserves excluding revaluation reserves	-	z	=	24,815.76	9,400.00 19,414.28
18	Earnings per equity share (for continuing operation):			_
	(1) Basic	0.16	0.14	0.10	0.57	0.34
19	(2) Diluted Earnings per equity share (for discontinued operation):	0.16	0.14	0.10	0.57	0.34
	(1) Basic
	(2) Diluted	Bs	7	-	-
20	Eamings per equity share (for discontinued & continuing	-	ee	=	:	7
	loperations) (1) Basic
	(2) Diluted	0.16 0.16	0.14 0.14	0.10 0.10	0.57	0.34
					0.57	0.34

Place: Indore

Vijay Shankarlal Bankdal Managing Director DIN: 00023027,

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 4, Pithampur, Dist: Dhar-454775

^EMail:- [email protected], Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY AND YEARLY AUDITED RESULTS

					Rs. In Lacs except EPS
S.No.			Quarter Ended		Year to date Ended
	Particulars	31-03-2025	31-12-2024	31-03-2024	34-03-2025	31-03-2024
		Audited	Unaudited	Audited	Audited	Audited
	Segment Revenue
	a) Pharmaceuticals Drugs & Formulations 'b) Trading of Commodities	16259.54	12839.41	7,454.52	47,027.33	26,218.06
	c) Renting of Property	213.45)	228,88	213.93	825,84	1,071.34
	Total Segment Revenue	108,93}	88,73]	98.67	391.49	401.89)
	Less: Inter Segment Revenue	15,581.92	13,157.02	7,767.12	48,244.66	27,691.29}
	Total Income	-	-	-	-
	Segment Results Profit(+)/Loss(-) before tax	15,581.92	13,157.02	7,767.12	48,244.66	27,691.29
	and interest from each segment
	a) Pharmaceuticals Drugs & Formulations
	b) Trading of Commodities	2237.06}	1662.02]	1,022.55	6 258,62	3,454.60)
	c) Renting of Property	4.19) 100.44	3.37	19.92	20.35	18.49)
	Total Profit before tax and Interest		80.65	80,03	358.79	369.62}
	Less: i) Interest	2,341.69 11.68	1,746.04	41,122.50)	6,637.76	3,842.71
	ii) Other Un-allocable Expenditure	0,00	19,82	119.51	86.49	447.41
	Profit before tax	2,330.01	0.00 1,726.22	0.00] 1,003.00	0,00)	0,00}
	(Segment Asset-Segment Liabilities)				6,551.27	3,395.30
	Segment Asset
	a) Pharmaceuticals Drugs & Formulations	36111.42	32946,55}	34,706.49
	b) Trading of Commodities	448,67]	890.60}	1,026.45.	36,111.42 448.67	34,706.49)
	c) Renting of Property	4767.98]	4733,45)	4,733.45	4,767.98	1,026.45 4,733.45
	Total Segment Asset	41,328.07	38,570.60	40,466.39	41,328.07,
	Un-allocable Assets	-	=	+	-	40,466.39) -
	Net Segment Asset	41,328.07	38,570.60	40,466.39	44,328.07	40,466.39
	Segment Liabilities
	a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities	6888. 49]	5663.64]	11,328.58	6,888.49	11,328.58}
	ic) Renting of Property	82.76]	155.00}	151.93	82.76	151.93}
	Total Segment Liabilities	141.04	77.43	171.60	141.04	171.60
	Un-allocable Liabilities	7,112.29	5,896.07	11,652.11	7,112.29	11,652.11
	Net Segment Liabilities		:	e	+	-
Notes:-		7,112.29	6,896.07,	11,652.14	7,112.29	11,652.11

¹The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 19/05/2025 2 These

Companies above Act, results 2013 have read been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time, ³

results The company are given is operating as required. in 3 segments i.e, (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise

⁴The Consolidated Statement of Assets and Liabllities as at 31st March, 2025 and the Consolidated Statement of Cash Flow is provided as an annexure to this statement.

5 Financial As required year under 2024-2025 Regulation 33 of SEB! (LODR) Regulations, 2015 the Auditor's report provided by the Statutory Auditors have carried out Audit books of Accounts for the the company is and issued us an Audit Report with an unmodified opinion on Audited financial Results for the Quarter / Year ended 31st March, 2025 Therefor not required to give statement of Impact of Audit Qualification for Audit report with modified opinion

⁶Previous period figures have been regroupedi/reclassified wherever necessary to confirm to this period classification.

7 that The financial figures of year the Last Quarter are the balancing figures between the audited figures in respect of full financial year & the published year to date figures upto 3rd quarter of

⁸The Company currently have 3 (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd, Sante Biotech Pvt. Ltd. and Vincit Biotech International Pvt. Ltd,

Place: Indore

Date: 19/05/2025

For, Syncom Formulations (India) Limited Vijay Shankarlal Bankda Managing Director DIN: 00023027

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off :- 7,Niraj Industrial Estate, Off Mahakali Caves Road,Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 4, Pithampur, Dist: Dhar-454775 E Mail:- [email protected], Website:- www.sfil.in, CIN :- L24239MH1988PLC047759
CONSOLIDATED Statement of Assets & Liabilities as at 31/03/2025
Particulars
Rs. In Lacs	31-03-2025 Audited	31-03-2024
ASSETS		Audited

Non-current assets
(a) Property, Plant and Equipment	7,752.61
(b) Capital Work in Progress	-	7,230.60
(c) Intangible assets	4.72	- 11.05
(d) Investment Property	4,733.44	4,733.44
(e) Financial Assets	-	-
(i) Investments	361.82	248.92
(ii) Fixed Deposits & Accrued Interest	1,330.52	691.67
(ii) Deposits	66.62	51,90
(f) Other Non Current Assets	81.58	20.56
Current assets	-	=
(a) Inventories	4,133.20	2,108.15
(b) Financial Assets	-	-
(i) Investments	8,921.64	6,369.94
(ii) Trade Receivables	10,754.85	10,329.84
(iii) Cash And Cash Equivalents	71.20	6,338.34
(iv) Bank Balances other than (iii) above	-	448,21
(v) Deposits	353.22	412.00
(vi) Loans & Advances d) Other Current Assets	543.53	427.78
Total	2,219.12	1,043.99
	41,328.07	40,466.39
EQUITY AND LIABILITIES
Equity
(a) Equity Share Capital	9,400.00	9,400.00
(b) Other Equity	24,815.76	19,414.28
Liabilities	-	-
Non Current Liabilities	es	-
(a) Financial Liabilities	-	-
(i) Trade and other Deposits	133.35	171.60
(b) Provisions	416.84	330.38
(c) Deferred Tax Liabilities (Net)	631.05	497.67
Current liabilities	=	-
(a) Financial liabilities	-	-
(i) Borrowings	458.36	7,248.66
(ii) Trade Payables Total Outstanding Dues of Micro Enterprises and Small Enterprises	-
ic Dues of Creditors other than Micro Enterprises and Small	2,281.33	594,34
	1 998.41	1 820.05
(iii) Other Financial Liabilities	213.00	213.62
(b) Other Current Liabilities c) Provisions	561.62	412.70
Total	418.35	363.09
	41,328.07	40,466.39

Fores:	a	ormulations (India) Limited
Place: Indore	gba	Ny ¢ Similan
if, oO Ss Date: 19/05/2025	OS Xo Vijay. Shankarlal Bankda Sy,
	' 4	Managing Director]

} DIN: 00023027

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775, ^EMail:- [email protected], Website:- www. sfilin, CIN : L24239MH1988PLC047759

CONSOLIDATED Cash Flow Statement for the year ended 31/03/2025
Particulars	31-03-2025	31-03-2024
Rs. In Lacs	Audited	Audited
Cash Flow from Operating Activities
Profit before extraordinary item and tax	6,550.69	3,397.69
Adjustments for:		-
Gain on Sale of Machinery / (Loss on Sale of Vehicle)	0.58	(2,39)
Gain/(Loss) on Actuarial valuation of employee benefits Depreciation	(28.91)	-
Depreciation Written Back	519,39	472.23
Finance Costs	(39.14)	(1.74)
Other Income	86.49	447.44
	(1,657.81)	(1,263.88)
Operating Profit before working capital changes
Changes in Working Capital	5,431.29	3,049.32
Inventory	(2,025.05)
Trade Receivables	(425.01)	11,88 (2,779.13)
Loans & Advances	(115.75)	(151.21)
Other Current Assets	(1,116.35)	(324.23)
'Trade Payables	1,865.35	369.70
Other Financial Liabilities	(0.62)	11.44
Other Current Liabilities	148.92	(76.33)
Short Term Provisions	55.26	101.18
Changes in Working Capital	(1,613.25)	(2,836.70)
Cash Generated from Operations before Tax	3,818.04	212.62
Less: Income Tax Paid	1,474.43	808.45
Net Cash From Operating Activities	2,343.61	(595.83)
Cash Flow from Investing Activities
Change in Property Plant and Equipment, Intangible Assets and
Capital Work in Progress	(986,85)
Change in Investment Property	-	(S1S:6¢) -
Change in Fixed Deposit & Accrued Interest	(190.64)	7,208.16
Change in Deposits	(14.72)	(2.15)
Change in Other Non Current Assets	(61,02)	155.58
Change in Trade & Other Deposits	(38.25)	17.46
Other Income	1,657.81	1,263.88
Change in Investment	(2,177.67)	472,67
Net Cash from Investing Activities	(1,820.42)	8,301.96
Cash Flow from Financing Activities
Finance Costs	(86.49)	(447.41)
Change in Long Term Liabilities	86,46	61.14
Issue of Warrants & Share capital	-	-
Dividend Paid	-	-
Borrowings	(6,790.30)	(1,069.49)
Net Cash from Financing Activities	(6,790.33)	(1,455.76)
Net Decrease in Cash & Cash Equivalents	(6,267.14)
Cash & Cash Equivalents at the beginning of the Period	6,338.34	6,250.37 87.97
Cash & Cash Equivalents at the End of Period	71.20	6,338.34

ncom Formulations (India) Limited Place: Indore Vos Date: 19/05/2025 h Oy Vijay Shankarlal Bankda Managing Director DIN: 00023027] the SEB! (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To, The Board of Directors Syncom Formulations (lndia) Limited